Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 Financial Results

Stock Track11-14

Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The biopharmaceutical company, which focuses on developing treatments for chronic cough and neurologically mediated disorders, reported figures that fell short of investor expectations.

The company's Q3 earnings report revealed a net loss of $11.802 million, translating to an earnings per share (EPS) of -$0.08. This substantial loss appears to have triggered a negative reaction from investors. Additionally, Trevi Therapeutics reported operating expenses of $13.916 million for the quarter, contributing to an income from operations of -$13.916 million.

These financial results suggest that Trevi Therapeutics continues to face challenges in its path to profitability. The significant operating expenses, coupled with the lack of revenue mentioned in the report, indicate that the company is still in its development phase and burning through cash. Investors may be concerned about the company's cash runway and its ability to bring its pipeline products to market without additional fundraising. The sharp stock decline reflects these concerns and the market's reassessment of Trevi Therapeutics' near-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173408137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173408137","market":"us","top_or_hot":-1,"title":"Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 Financial Results","media":"Stock Track","content":"<p>Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The biopharmaceutical company, which focuses on developing treatments for chronic cough and neurologically mediated disorders, reported figures that fell short of investor expectations.</p>\n\n<p>The company's Q3 earnings report revealed a net loss of $11.802 million, translating to an earnings per share (EPS) of -$0.08. This substantial loss appears to have triggered a negative reaction from investors. Additionally, Trevi Therapeutics reported operating expenses of $13.916 million for the quarter, contributing to an income from operations of -$13.916 million.</p>\n\n<p>These financial results suggest that Trevi Therapeutics continues to face challenges in its path to profitability. The significant operating expenses, coupled with the lack of revenue mentioned in the report, indicate that the company is still in its development phase and burning through cash. Investors may be concerned about the company's cash runway and its ability to bring its pipeline products to market without additional fundraising. The sharp stock decline reflects these concerns and the market's reassessment of Trevi Therapeutics' near-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The biopharmaceutical company, which focuses on developing treatments for chronic cough and neurologically mediated disorders, reported figures that fell short of investor expectations.</p>\n\n<p>The company's Q3 earnings report revealed a net loss of $11.802 million, translating to an earnings per share (EPS) of -$0.08. This substantial loss appears to have triggered a negative reaction from investors. Additionally, Trevi Therapeutics reported operating expenses of $13.916 million for the quarter, contributing to an income from operations of -$13.916 million.</p>\n\n<p>These financial results suggest that Trevi Therapeutics continues to face challenges in its path to profitability. The significant operating expenses, coupled with the lack of revenue mentioned in the report, indicate that the company is still in its development phase and burning through cash. Investors may be concerned about the company's cash runway and its ability to bring its pipeline products to market without additional fundraising. The sharp stock decline reflects these concerns and the market's reassessment of Trevi Therapeutics' near-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRVI","symbol_name":"Trevi Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1173408137","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173408137","pubTimestamp":1763068113,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRVI":"Trevi Therapeutics Inc."},"translate_title":"个股追踪|Trevi Therapeutics第三季度财报令人失望后暴跌5.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":1},"content_text":"Trevi Therapeutics, Inc. (NASDAQ: TRVI) saw its stock price plummet by 5.57% during Thursday's intraday trading session following the release of its third-quarter 2025 financial results. The biopharmaceutical company, which focuses on developing treatments for chronic cough and neurologically mediated disorders, reported figures that fell short of investor expectations.\nThe company's Q3 earnings report revealed a net loss of $11.802 million, translating to an earnings per share (EPS) of -$0.08. This substantial loss appears to have triggered a negative reaction from investors. Additionally, Trevi Therapeutics reported operating expenses of $13.916 million for the quarter, contributing to an income from operations of -$13.916 million.\nThese financial results suggest that Trevi Therapeutics continues to face challenges in its path to profitability. The significant operating expenses, coupled with the lack of revenue mentioned in the report, indicate that the company is still in its development phase and burning through cash. Investors may be concerned about the company's cash runway and its ability to bring its pipeline products to market without additional fundraising. The sharp stock decline reflects these concerns and the market's reassessment of Trevi Therapeutics' near-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173408137","isCrawlerRequest":true}